SENTI-202 AML Cell Therapy Completes Phase 1 Enrollment
SOUTH SAN FRANCISCO, Calif., Feb. 11, 2026 — Senti Biosciences announced the completion of patient enrollment in its Phase...
Alzheimer’s Disease Animal Health Bio-Pharma biologics biopharma biopharma innovation Biotechnology Cell Therapy cGxP cGxP compliance Clinical-Stage Biotech Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy GMP compliance Immuno-Oncology immunology Immunotherapy Johnson & Johnson Medical Devices MedTech medtech innovation Oncology oncology innovation Orphan Drug orphan drug designation patient access Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine Regulatory Affairs regulatory approval regulatory compliance Sanofi targeted therapy
SOUTH SAN FRANCISCO, Calif., Feb. 11, 2026 — Senti Biosciences announced the completion of patient enrollment in its Phase...
